Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
What systemic therapy would you offer a patient with metastatic melanoma who is BRAF WT and developed metastases while on adjuvant nivolumab?
Related Questions
Among the metastatic/unresectable melanoma patients you would historically treat with anti-PD-1 monotherapy, are you now recommending nivolumab/relatlimab instead?
Do you consider downstaging neoadjuvant cemipilimab for borderline resectable CSCC in order to facilitate surgical resection?
Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?
Is the phase 2 data regarding neoadjuvant cemiplimab in cutaneous squamous cell carcinoma sufficient to adopt for all patients or will you await phase 3 data?
Would you offer adjuvant therapy for a patient with Stage IIIB melanoma (pT2aN1c) (microsatellite only) following wide excision with negative SLN?
Is there evidence that amputation of the affected digit, removal of involved lymph node(s), or CLND lengthens or improves the quality of life in patients with subungual melanoma with palpable ipsilateral axillary nodal mets being treated with appropriate Immuno/checkpoint inhibitors?
In what scenario would you consider dual IO and TKI therapy in advanced stage melanoma?
Any role for adjuvant systemic therapy for resected sebaceous skin carcinoma?
